Merck & Co., Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 5, 2023 and accepted by EDGAR at May 5, 2023, 07:39 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $14.49bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $3.93bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $4.28bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $2.48bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $242.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $825.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $2.82bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $1.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $1.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 2,551,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $1.34bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 3 months2023-01-01 to 2023-03-31 | $1.85bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2023-01-01 to 2023-03-31 | $149.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $9.71bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $33.40bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $107.80bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $23.13bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-03-31 | $28.07bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-03-31 | $2.67bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-03-31 | $46.83bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-015990. Last ingested by Listed: Oct 29, 2026, 06:44 ET. Listed shows no prices and gives no investment advice.